Given that MARCO+ TAMs suppress antitumor immunity of CD8+ CTLs by impairing tumor recognition, we hypothesized that restoring the antigen presentation process by MARCO blockade would likewise recover the tumor recognition by eliciting anti‐tumor activity and boost ICB therapeutic efficacy. This evidence concerns the gene CD8A and neoplasm.